Business Wire

BALDERTON-CAPITAL

7.2.2020 13:03:07 CET | Business Wire | Press release

Share
Balderton Capital, Europe’s Most Active Series A Investor, Welcomes Two New General Partners

Balderton Capital announces today that it has hired two new General Partners. Rana Yared joins from Goldman Sachs, where she was Partner in the Principal Strategic Investments team. David Thévenon joins from SoftBank’s Vision Fund, where he was one of the initial Partners.

Bernard Liautaud, Managing Partner of Balderton Capital, said: "I am delighted to welcome Rana and David to the partnership. They both bring outstanding experience in investing globally in the technology ecosystem. With her team at Goldman Sachs, Rana has built one of the best fintech and AI portfolios across the US and Europe. And within Softbank, David has participated in the growth journeys of companies as diverse as Didi in China, Grab in Singapore, Lemonade and SoFi in the US. The opportunity in the European tech ecosystem continues to expand at a rapid pace, and Rana and David will play a key role in our investment strategy in the European venture space."

During her time at Goldman Sachs, Rana’s team invested $2bn in 80 companies, with a strong focus on fintech. As one of Goldman’s best-known tech investors, Rana led the US and European Principal Strategic Investment (PSI) teams and served on Goldman’s Growth Equity Investment committee. She spent five years on the board of the fixed income trading platform Tradeweb, until it went public in April 2019 with a market capitalisation of $6bn. Rana also brought the artificial intelligence platform Kensho to Goldman Sachs. Kensho was ultimately sold to S&P Global for $550m in March 2018.

Rana currently sits on the boards of Nutmeg, Vestwell, NAV, Pensando, Digital Reasoning, Veem, and NYSHEX. She joined Goldman Sachs as an analyst in 2006 and was named Managing Director in 2013 and Partner in 2018.

Rana Yared said: “My greatest passion is working closely with founders and their teams to build new companies, and I am delighted to be able to devote myself to this when I join Balderton. In recent years, Europe has established itself as a tech leader and is brimming with potential and opportunity. I am excited to move back to the European side of the Atlantic and to begin seeking out and working with the next generation of exciting tech companies.”

During his five-year tenure at SoftBank, David led investments in Didi Chuxing, the world's leading mobile transportation platform; Grab, Southeast Asia's leading superapp; Ola, India's leading ride-sharing platform; Lemonade, the digital insurance company powered by AI and driven by social good; SoFi, the American online personal finance platform; and Kabbage, one of the leading US SMB lending platforms. David was also involved in SoftBank's investments in 99 in Brazil (bought by Didi) and Legendary Pictures in the US (sold to Wanda Group).

Before joining SoftBank, David had a 10-year career at Google, where he worked on partnerships for products that touched billions of users, including leading global product and business partnerships for Google's Android platform.

David Thévenon said: “Five years ago I left Google to focus on venture investing at SoftBank and I felt privileged to meet, invest and work with some of the most innovative and visionary founders, supporting them as they grew into market-leading companies. Joining Balderton will allow me to continue this for European-founded companies, and I am truly excited about the opportunity ahead.”

[ENDS]

About Balderton:
Balderton Capital is a London-based venture firm focused exclusively on backing the best European-founded technology companies. In the two decades since our founding, we have worked with hundreds of extraordinary European founders, and have raised eight funds totalling more than $3bn. Balderton’s most recent funds were the early-stage Balderton VII, raised in November 2019, and Liquidity I, Europe’s first venture fund dedicated to secondary investments in European-founded, growth-stage technology startups, raised in October 2018. Previous exited investments include Betfair (FTSE: BET), Magic Pony (Twitter), NaturalMotion (Zynga), Recorded Future (Insight Partners), Sunrise (Microsoft), Talend (NASDAQ: TLND) and Yoox Net-a-Porter (BIT: YNAP). Among Balderton’s current portfolio of over 90 companies are Aircall, Carwow, Citymapper, Contentful, Darktrace, Depop, GoCardless, The Hut Group, Kobalt Music, Nutmeg, Peakon, Prodigy Finance, Revolut, SOPHiA Genetics, Tessian, Vestiaire Collective, Vivino, Voi Technology, and Zego.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release

The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a

SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release

Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye